Clinical Trial Update: APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for APG-1252 as monotherapy or in combination for relapsed or refractory non-Hodgkin lymphoma is in Phase 1/Phase 2, with status current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• APG-1252 (APG-1252)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: NHL, Adult | Phase 1, Phase 2 | Status: UNKNOWN